Gilead Sciences is a research-based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics in areas of unmet medical need. Its work spans virology, oncology, and inflammatory diseases, with a portfolio that includes treatments fundamentally transforming care for HIV and the first cure for hepatitis C.
The company employs more than 17,000 people and maintains operations in over 35 countries. It invests billions annually in research and development to advance its pipeline across its core therapeutic areas.
Gilead works to expand access to its treatments through partnerships, pricing initiatives, and patient assistance programs globally, with a stated focus on addressing health inequities.
